Top 5 Papers
#1
Source: Lancet Oncology | Authors: Paolucci I, Overduin CG, Johnston EW, et al. (ESSO/CIRSE/SIO multisociety consensus) | Published: May 2026 (Lancet Oncol 27:e248-e258)
Score: 12/20 — Base 9 (Lancet Oncology) + 3 (new standard of care framework — first international consensus for ablation margin assessment in HCC and CRC liver mets)
First international, multisociety, multidisciplinary Delphi consensus to standardize ablation margin assessment in liver tumor thermal ablation (HCC and CRC liver metastases). 72 experts from North America, South America, Europe, and Asia reached formal consensus on 150 of 199 statements (75%) across two online surveys and a hybrid Innsbruck meeting. Key recommendations: ablation margins must be assessed and documented for every treated tumor; assessment should be quantitative in three dimensions using contrast-enhanced CT or MRI, preferably intraprocedurally with ablation confirmation software; and a new uniform classification — A0 (tumor completely covered with sufficient margin), A1 (tumor completely covered but insufficient margin), A2 (portion of tumor remains unablated) — should replace heterogeneous local terminology. Strong agreement between interventional radiologists and surgical oncologists (only 12 statements, 6%, showed significantly different ratings). Endorsed by ESSO, CIRSE, and SIO. This sets the global benchmark for what an adequate ablation looks like and how to document it.
Post angle: Liver ablation finally has a margin rulebook. New A0/A1/A2 classification + 3D quantitative margins + intraprocedural confirmation software become the international standard for HCC and CRC liver mets. #HCC #CRC #LiverMets #InterventionalOncology #GIOnc
#2
Source: Lancet Oncology | Authors: Laimer G, Johnston EW, Overduin CG, et al. (ESSO/CIRSE/SIO multisociety consensus) | Published: May 2026 (Lancet Oncol 27:e259-e270)
Score: 12/20 — Base 9 (Lancet Oncology) + 3 (new SOC framework — first international procedural and credentialing standards for liver thermal ablation)
Companion Lancet Oncology Delphi consensus defining procedural and practice standards for liver tumor thermal ablation across HCC and CRC liver mets. 72 multidisciplinary experts engaged in three iterative rounds across 135 statements grouped into five domains: credentialing, indications, approach, procedural factors, and safety measures. Consensus achieved on 94 of 135 statements (70%). Key recommendations: the least invasive route — typically percutaneous — should be prioritized; margin adequacy is reaffirmed as the principal technical goal; organ displacement techniques are endorsed to maintain safety and expand treatable indications; complex ablations should be performed by experienced operators with more than 100 previous cases, supported by structured training, multidisciplinary team participation, and routine audit. Future efforts should develop validated difficulty-scoring systems, standardized procedural reporting templates, and comprehensive training curricula. Together with the margin paper, this is the most comprehensive procedural governance framework yet published for thermal ablation of liver tumors.
Post angle: Companion Lancet Onc consensus: liver ablation needs >100-case credentialing for complex cases, percutaneous-first approach, and structured MDT review. Practice variation in HCC and CRC liver mets ablation is no longer acceptable. #HCC #CRC #LiverMets #GIOnc
#3
Source: Signal Transduction and Targeted Therapy | Authors: Tang J, Wang L, Yang S, et al. (Nanjing Medical University) | Published: May 4, 2026
Score: 8/20 — Base 5 (Sig Transduct Target Ther) + 2 (Phase II) + 1 (precision/biomarker — MSS/pMMR is historically immunotherapy-resistant)
Single-arm, open-label Phase II study (n=33) of total neoadjuvant chemotherapy (CapOX) combined with PD-1 blockade (sintilimab) and interleukin-2 in microsatellite stable / proficient MMR locally advanced rectal cancer — a population that has historically failed immunotherapy. After 6 cycles, all 33 patients underwent radical surgery with a 100% R0 resection rate. Pathological complete response rate was 42.4% (95% CI 25.7–59.2%); the remaining 19 patients (57.6%) had partial responses. TRG distribution: TRG1 9.1%, TRG2 42.4%, TRG3 6.1%. Grade 3 AEs in 21.2%; no grade 4–5 events, no treatment-related deaths, no anastomotic leakage or bowel obstruction. With median follow-up of 25.5 weeks, no recurrences were observed. Translational analyses showed significant activation of CD8 T cells, NK cells, and M1 macrophages in the tumor microenvironment of patients achieving pCR. While early follow-up and small N temper enthusiasm, a 42% pCR in MSS/pMMR LARC dramatically exceeds historical TNT benchmarks (~25–30%) and warrants randomized validation.
Post angle: MSS/pMMR rectal cancer + immunotherapy = historically dismal. Adding sintilimab + IL-2 to TNT delivered 42.4% pCR & 100% R0 in 33 pts with 0 recurrences at 25.5 wks. Could rewrite the immune-cold rectal playbook. #CRC #RectalCancer #Immunotherapy #GIOnc
#4
Source: European Journal of Gastroenterology & Hepatology | Authors: Rafi R, Yasmin N, Ghani M, et al. | Published: April 28, 2026
Score: 7/20 — Base 5 (Eur J Gastroenterol Hepatol) + 2 (systematic review + Bayesian network meta-analysis)
Largest head-to-head comparison of commercial AI colonoscopy systems to date: 48 RCTs / 34,106 participants pooled in a Bayesian network meta-analysis. All AI-assisted systems significantly improved adenoma detection rate (ADR) versus standard colonoscopy. Ranking by ADR effect: EndoAngel (OR 1.84, SUCRA 0.9) > EndoAID (OR 1.64, SUCRA 0.7) > CAD-EYE (OR 1.46, SUCRA 0.5) ≈ GI Genius (OR 1.45, SUCRA 0.5). For adenomas per colonoscopy (APC), EndoAID showed the largest benefit (mean difference 0.62). EndoAngel modestly increased withdrawal time (+1.14 minutes). Critically, no system significantly improved detection of advanced adenomas or sessile serrated lesions — the lesions that drive interval cancers. Heterogeneity was low, certainty of evidence moderate. Practical takeaway: AI improves ADR uniformly across vendors but advances in detecting high-risk lesions remain elusive; head-to-head trials and cost-effectiveness studies are now urgently needed.
Post angle: Largest AI colonoscopy meta-analysis (48 RCTs, 34k pts): EndoAngel > EndoAID > CAD-EYE > GI Genius for ADR — but NO system improved advanced adenoma or sessile serrated detection. AI helps the easy lesions, not the dangerous ones. #CRC #AI #Colonoscopy #GIOnc
#5
Source: ESMO Gastrointestinal Oncology (Article in Press) | Authors: ESMO Gastrointestinal Oncology — surfaced via @DraMartinezLago + @OncoAlert (X) | Published: May 2026 (article in press)
Score: 8/20 — Base 5 (ESMO Gastrointestinal Oncology, Other journal tier) + 1 (biomarker-guided / ctDNA precision-medicine framework) + 2 (Colleague Engagement bonus — engaged by 2 distinct curated GI oncology KOLs: @DraMartinezLago original post + @OncoAlert repost)
Article-in-press in ESMO Gastrointestinal Oncology surfaced this week through high-engagement KOL discussion (@DraMartinezLago, reposted by @OncoAlert) on the long-debated question of when to stop immune checkpoint inhibitors in patients with MSI-H/dMMR metastatic colorectal cancer who have achieved disease control. Core observations driving the discussion: early ICI discontinuation (<2 years of treatment) in responders does not incur a measurable PFS or OS penalty; circulating tumor DNA (ctDNA) negative status (~80% of long-term responders) confers very low relapse risk and supports safe treatment cessation; ctDNA-positive status, conversely, signals higher progression risk and identifies patients who likely benefit from continued ICI exposure or early treatment switch. The paper frames the field's shift away from arbitrary fixed-duration ICI strategies (often 2 years) toward biomarker-stratified, ctDNA-guided treatment duration in dMMR/MSI-H mCRC — directly relevant to the long-tail of KEYNOTE-177 and CheckMate-8HW responders now reaching the 2-year mark in routine practice. Practical implication for the oncology clinic: serial ctDNA monitoring may become the rate-limiting decision step for stopping vs continuing ICI in this population, with significant cost, toxicity, and quality-of-life consequences.
Post angle: When to stop pembro/nivo-ipi in dMMR/MSI-H mCRC responders? New ESMO GI Onc article-in-press: <2y discontinuation looks safe in ctDNA− pts (~80% of responders); ctDNA+ flags relapse risk. ctDNA-guided stopping rules are coming. #CRC #MSI #dMMR #ctDNA #Immunotherapy #GIOnc
Additional Papers of Interest
-
International Journal of Cancer — Higher daytime light (≥1,916 lux) associated with reduced GI cancer incidence (HR 0.87) and mortality (HR 0.76); strongest signal in pancreatic cancer (incidence HR 0.58, mortality HR 0.47, n=89,069 prospective cohort).
-
World Journal of Surgical Oncology — Meta-analysis of 21 SSA studies (410 patients, 2014–2024): stomach 64.1% of GIST sites; 70% surgical resection (R0 68.2%); pooled DCR 77.3%; pooled mOS 44.0 months despite imatinib access disparities.
-
Lancet Oncology Commission — Diagnosed cancer incidence projected from 13.58M (2025) to 19.32M (2050); 31.5% of cancer deaths globally are undiagnosed (0.9% in Western Europe vs 67.4% in Western Africa). GI cancers (esophagus, stomach, CRC, anus, liver, pancreas) explicitly modeled.
-
Journal of Clinical Oncology — Editorial commentary on the safety of organ-preservation watch-and-wait strategy in patients with near-complete (rather than complete) clinical response after total neoadjuvant therapy.
-
BMC Cancer — Five-lncRNA cuproptosis signature derived from TCGA stratifies HCC overall survival; LINC02505 functionally validated as a risk factor in HCC cell lines, supporting cuproptosis as a therapeutic vulnerability in liver cancer.
-
Cancer Biology & Therapy — Preclinical demonstration that parthenolide binds UBD and activates ferroptosis (↑iron, ↑lipid peroxides, ↓GPX4) in iCCA cells and xenograft mice, with partial rescue by ferrostatin-1.
Back to all digests